Related Experiment Videos
Optimization of the RT-PCR technique to detect melanoma cells in peripheral blood
Ana Suárez1, Joaquín Fra, Rebeca Alonso
1Department of Functional Biology, Hospital Central de Asturias, Universidad de Oviedo, Spain.
Abstract:
Detection of melanoma cells in the peripheral blood of melanoma patients by reverse transcription polymerase chain reaction techniques has demonstrated varying detection rates. This study examined the sensitivity of the technique by employing a modification of the currently used protocols to detect mRNA markers. RT-PCR of tyrosinase and MART-1 was performed after poly A+-RNA isolation from unmanipulated whole blood lysed in the presence of nuclease inhibitors. We found a preclinical sensitivity of 1 GR-M melanoma cell spiked in 1 ml of blood. The clinical sensitivity was tested by studying 22 melanoma patients with advanced disease. The rate of positivity in all patients was 63.6% for tyrosinase, 50% for MRT-1 and 77.3% for at least one molecular marker. This figure increased to 89.5% when considering only those patients with evident macroscopic disease. We can conclude that the technical modifications introduced in this protocol significantly increased the clinical sensitivity compared with other published methods.
Insights
This study improved reverse transcription polymerase chain reaction (RT-PCR) for detecting melanoma cells in blood. Enhanced RT-PCR protocols increased clinical sensitivity for melanoma detection in advanced cancer patients.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Detection of melanoma cells in peripheral blood using reverse transcription polymerase chain reaction (RT-PCR) has shown variable success rates.
- Existing RT-PCR methods for melanoma cell detection require optimization for improved sensitivity and reliability in clinical settings.
Purpose of the Study:
- To enhance the sensitivity of RT-PCR for detecting melanoma cells in peripheral blood.
- To evaluate the clinical utility of modified RT-PCR protocols for identifying melanoma cell markers (tyrosinase and MART-1) in advanced melanoma patients.
Main Methods:
- Modified RT-PCR protocols were developed to detect messenger RNA (mRNA) markers, specifically tyrosinase and MART-1.
- Polyadenylated RNA (poly A+-RNA) was isolated from whole blood treated with nuclease inhibitors.
- Preclinical sensitivity was assessed by spiking known numbers of GR-M melanoma cells into blood samples.
Main Results:
- The modified RT-PCR demonstrated a preclinical sensitivity of detecting 1 GR-M melanoma cell per 1 ml of blood.
- In 22 advanced melanoma patients, positivity rates were 63.6% for tyrosinase, 50% for MART-1, and 77.3% for at least one marker.
- For patients with evident macroscopic disease, the detection rate for at least one marker increased to 89.5%.
Conclusions:
- Technical modifications significantly improved the clinical sensitivity of RT-PCR for melanoma cell detection compared to previously published methods.
- The enhanced RT-PCR protocol shows promise for more effective monitoring and diagnosis of melanoma in patients with advanced disease.